MEI Pharma Inc (MEIP)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:MEI Pharma Inc (MEIP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014326
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
MEI Pharma Inc (MEI), formerly Marshall Edwards Inc is an oncology company that offers clinical development of novel therapies for cancer. The company’s drug candidates comprise pracinostat, an oral HDAC inhibitor which is intended for the treatment of acute myeloid leukemia, myelodysplastic syndrome and myelofibrosis. Its also develops ME-344, a mitochondrial inhibitor for the treatment of HER2-negative Breast indication; and ME-401, an oral PI3K delta inhibitor for B-cell malignancies. The company partners with other drug developers to produce Pracinostat in AML and myelodysplastic syndrome indications. MEI is headquartered in San Diego, California, the US.

MEI Pharma Inc (MEIP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
MEI Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
MEI Pharma Acquires PWT143 From Pathway Therapeutics 12
MEI Pharma Completes Acquisition Of Rights To Pracinostat From S*BIO For Up To US$76 Million 13
Marshall Edwards Completes Acquisition Of Intellectual Property Portfolio From Novogen 15
Partnerships 17
Helsinn Enters into Agreement with MEI Pharma 17
Licensing Agreements 18
MEI Pharma Enters into Licensing Agreement with Presage Biosciences 18
Helsinn Enters into Licensing Agreement with MEI Pharma 19
MEI Pharma Enters into Licensing Agreement with Ligand Pharma 20
MEI Pharma Enters into Licensing Agreement with CyDex Pharma 21
Marshall Edwards Enters Into Licensing Agreement With Ausio Pharma 22
Equity Offering 23
MEI Pharma Raises USD46 Million in Public Offering of Shares 23
MEI Pharma Completes Public Offering Of Shares For US$35 Million 25
MEI Pharma Completes Public Offering Of Shares For US$15 Million 26
MEI Pharma Completes Private Placement Of Units For US$27.5 Million 27
Marshall Edwards Completes Rights Offering Of Units For US$5.2 Million 29
Marshall Edwards Completes Private Placement Of Common Stock For US$2 Million 30
Marshall Edwards Completes Private Placement Of Common Stock For US$2 Million 32
Marshall Edwards Completes Private Placement Of Common Stock For US$1.1 Million 33
Marshall Edwards Completes First Tranche Of Public Offering Of Common Stock For US$0.13 Million 35
MEI Pharma Inc – Key Competitors 36
MEI Pharma Inc – Key Employees 37
MEI Pharma Inc – Locations And Subsidiaries 38
Head Office 38
Recent Developments 39
Financial Announcements 39
Nov 08, 2017: MEI Pharma Reports First Quarter Fiscal Year 2018 Results 39
Sep 05, 2017: MEI Pharma Reports Fiscal Year 2017 Results 40
May 04, 2017: MEI Pharma Reports Third Quarter Fiscal Year 2017 Results 42
Feb 08, 2017: MEI Pharma Reports Second Quarter Fiscal Year 2017 Results 43
Nov 09, 2016: MEI Pharma Reports First Quarter Fiscal Year 2017 Results 45
Sep 06, 2016: MEI Pharma Reports Fiscal Year 2016 Results 47
Corporate Communications 49
Apr 03, 2017: MEI Pharma Announces Appointment of Brian Drazba as Chief Financial Officer 49
Product News 50
06/03/2016: Presage Biosciences Appoints David Johnson to Board of Directors 50
Clinical Trials 51
Apr 19, 2016: Presage Biosciences Presents Data Demonstrating Tumor Growth Inhibition by Voruciclib and Proteasome Inhibitors Superior to Single Agents in Model of Triple Negative Breast Cancer 51
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52

List of Tables
MEI Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
MEI Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
MEI Pharma Inc, Deals By Therapy Area, 2011 to YTD 2017 9
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
MEI Pharma Acquires PWT143 From Pathway Therapeutics 12
MEI Pharma Completes Acquisition Of Rights To Pracinostat From S*BIO For Up To US$76 Million 13
Marshall Edwards Completes Acquisition Of Intellectual Property Portfolio From Novogen 15
Helsinn Enters into Agreement with MEI Pharma 17
MEI Pharma Enters into Licensing Agreement with Presage Biosciences 18
Helsinn Enters into Licensing Agreement with MEI Pharma 19
MEI Pharma Enters into Licensing Agreement with Ligand Pharma 20
MEI Pharma Enters into Licensing Agreement with CyDex Pharma 21
Marshall Edwards Enters Into Licensing Agreement With Ausio Pharma 22
MEI Pharma Raises USD46 Million in Public Offering of Shares 23
MEI Pharma Completes Public Offering Of Shares For US$35 Million 25
MEI Pharma Completes Public Offering Of Shares For US$15 Million 26
MEI Pharma Completes Private Placement Of Units For US$27.5 Million 27
Marshall Edwards Completes Rights Offering Of Units For US$5.2 Million 29
Marshall Edwards Completes Private Placement Of Common Stock For US$2 Million 30
Marshall Edwards Completes Private Placement Of Common Stock For US$2 Million 32
Marshall Edwards Completes Private Placement Of Common Stock For US$1.1 Million 33
Marshall Edwards Completes First Tranche Of Public Offering Of Common Stock For US$0.13 Million 35
MEI Pharma Inc, Key Competitors 36
MEI Pharma Inc, Key Employees 37

★海外企業調査レポート[MEI Pharma Inc (MEIP)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Voyager Therapeutics Inc (VYGR):企業の財務・戦略的SWOT分析
    Summary Voyager Therapeutics Inc (Voyager) is a clinical-stage gene therapy company that develops treatments for patients suffering from severe neurological diseases. The company provides treatment for adeno-associated virus gene therapy field by selecting, designing and manufacturing vectors. Its c …
  • Sunflower Electric Power Corporation:企業の戦略的SWOT分析
    Sunflower Electric Power Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Akebia Therapeutics Inc (AKBA):企業の財務・戦略的SWOT分析
    Summary Akebia Therapeutics Inc (Akebia Therapeutics) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics based on hypoxia inducible factor for patients with kidney disease and other metabolic disorders. Its lead product candidate vadadustat is a HIF …
  • Stellar Resources Ltd:企業の戦略・SWOT・財務分析
    Stellar Resources Ltd - Strategy, SWOT and Corporate Finance Report Summary Stellar Resources Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Federal Signal Corp (FSS):企業の財務・戦略的SWOT分析
    Federal Signal Corp (FSS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Patara Pharma Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Patara Pharma Inc (Patara Pharma) is a clinical-stage biopharmaceutical company that develops novel therapies for the treatment of chronic inflammatory and fibrosis. The company develops anti-inflammatory therapeutics for lung diseases and immune disorders. It conducts clinical trials and in …
  • YTL Power International Berhad (YTLPOWR):企業の財務・戦略的SWOT分析
    YTL Power International Berhad (YTLPOWR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Dentsply Sirona, Inc.:企業の戦略・SWOT・財務情報
    Dentsply Sirona, Inc. - Strategy, SWOT and Corporate Finance Report Summary Dentsply Sirona, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Abu Dhabi National Energy Co (TAQA):石油・ガス:M&Aディール及び事業提携情報
    Summary Abu Dhabi National Energy Company (TAQA), a subsidiary of government-owned Abu Dhabi Water and Electricity Authority, is an energy and water company. It undertakes power generation; exploration, development, production and storage of oil and gas; pipelines and gas storage; and water desalina …
  • Procaps SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary Procaps SAS (Procaps) is a manufacturing and commercializing company that provides pharmaceutical forms. The company provides softigel products such as RX products, OTC products, natural products, omega 3 fish oils, gummies and veterinary products, among others. Its hospitalaria unit offers …
  • Chesapeake Energy Corp (CHK):企業の財務・戦略的SWOT分析
    Chesapeake Energy Corp (CHK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Davide Campari-Milano S.p.A.:戦略・SWOT・企業財務分析
    Davide Campari-Milano S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Davide Campari-Milano S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Proximus SA (formerly Belgacom SA):戦略・SWOT・企業財務分析
    Proximus SA (formerly Belgacom SA) - Strategy, SWOT and Corporate Finance Report Summary Proximus SA (formerly Belgacom SA) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Henry Schein, Inc.:企業のM&A・事業提携・投資動向
    Henry Schein, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Henry Schein, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Bassett Furniture Industries, Incorporated (BSET):企業の財務・戦略的SWOT分析
    Bassett Furniture Industries, Incorporated (BSET) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • National Fertilizers Ltd (NFL):企業の財務・戦略的SWOT分析
    Summary National Fertilizers Ltd (NFL) is a chemical company that develops, manufactures and markets urea, bio-fertilizers and other industrial products. The company’s bio-fertilizers comprise phosphorous bio-fertilizers and nitrogenbio-fertilizers. Its industrial products include ammonium nitrate, …
  • Illumina Inc (ILMN)-医療機器分野:企業M&A・提携分析
    Summary Illumina, Inc. (Illumina) provides genomic sequencing and array-based solutions for genetic analysis in the areas of molecular diagnostics, translational and consumer genomics, and oncology. The company’s portfolio encompasses sequencing tools and systems; sequencing kits and reagents; micro …
  • EQUATE Petrochemical Co:企業の戦略的SWOT分析
    EQUATE Petrochemical Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • ING Life Insurance Company Korea, Ltd.:企業の戦略・SWOT・財務情報
    ING Life Insurance Company Korea, Ltd. - Strategy, SWOT and Corporate Finance Report Summary ING Life Insurance Company Korea, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • China XD Plastics Co Ltd (CXDC):企業の財務・戦略的SWOT分析
    China XD Plastics Co Ltd (CXDC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆